share_log

Corient Capital Partners LLC Has $259,000 Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Corient Capital Partners LLC Has $259,000 Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Corient Capital Partners LLC拥有25.9万美元的BioMarin制药公司股票头寸(纳斯达克代码:BMRN)
Defense World ·  2022/11/27 08:21

Corient Capital Partners LLC lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 20.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,126 shares of the biotechnology company's stock after purchasing an additional 530 shares during the quarter. Corient Capital Partners LLC's holdings in BioMarin Pharmaceutical were worth $259,000 as of its most recent SEC filing.

Corient Capital Partners LLC在最近一次向美国证券交易委员会提交的13F文件中称,该公司在第二季度增持了BioMarin Pharmtics Inc.的股份20.4%。该机构投资者在本季度额外购买了530股后,持有这家生物技术公司的3126股股票。截至最近提交给美国证券交易委员会的文件,Corient Capital Partners LLC持有的BioMarin Pharmtics股份价值25.9万美元。

Several other large investors also recently modified their holdings of the stock. Acadian Asset Management LLC lifted its position in shares of BioMarin Pharmaceutical by 395.4% during the 1st quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company's stock worth $32,000 after buying an additional 344 shares during the last quarter. First Horizon Advisors Inc. lifted its position in shares of BioMarin Pharmaceutical by 1,014.6% during the 2nd quarter. First Horizon Advisors Inc. now owns 535 shares of the biotechnology company's stock worth $43,000 after buying an additional 487 shares during the last quarter. Covington Capital Management lifted its position in shares of BioMarin Pharmaceutical by 40.8% during the 2nd quarter. Covington Capital Management now owns 704 shares of the biotechnology company's stock worth $58,000 after buying an additional 204 shares during the last quarter. CWM LLC lifted its position in shares of BioMarin Pharmaceutical by 60.4% during the 2nd quarter. CWM LLC now owns 781 shares of the biotechnology company's stock worth $65,000 after buying an additional 294 shares during the last quarter. Finally, Desjardins Global Asset Management Inc. lifted its position in shares of BioMarin Pharmaceutical by 43.2% during the 2nd quarter. Desjardins Global Asset Management Inc. now owns 815 shares of the biotechnology company's stock worth $67,000 after buying an additional 246 shares during the last quarter. 94.84% of the stock is owned by institutional investors and hedge funds.

其他几家大型投资者最近也调整了对该股的持股比例。Acadian Asset Management LLC在第一季度将其在BioMarin制药公司的股票头寸提高了395.4%。Acadian Asset Management LLC现在持有这家生物技术公司431股股票,价值3.2万美元,上个季度又购买了344股。First Horizon Advisors Inc.在第二季度将其在BioMarin制药公司的股票头寸提高了1,014.6%。First Horizon Advisors Inc.现在持有535股这家生物技术公司的股票,价值43,000美元,在上个季度又购买了487股。卡温顿资本管理公司在第二季度将其在BioMarin制药公司的股票头寸提高了40.8%。卡温顿资本管理公司在上个季度又购买了204股,现在拥有704股这家生物技术公司的股票,价值5.8万美元。Cwm LLC在第二季度将其在BioMarin制药公司的股票头寸提高了60.4%。Cwm LLC现在持有这家生物技术公司781股股票,价值6.5万美元,在上个季度又购买了294股。最后,Desjardins Global Asset Management Inc.在第二季度将其在BioMarin制药公司的股票头寸提高了43.2%。Desjardins Global Asset Management Inc.现在持有这家生物技术公司815股股票,价值6.7万美元,上个季度又购买了246股。94.84%的股票由机构投资者和对冲基金持有。

Get
到达
BioMarin Pharmaceutical
BioMarin制药公司
alerts:
警报:

BioMarin Pharmaceutical Trading Down 0.9 %

BioMarin制药公司股价下跌0.9%

Shares of BioMarin Pharmaceutical stock opened at $96.92 on Friday. BioMarin Pharmaceutical Inc. has a 52 week low of $70.73 and a 52 week high of $99.74. The stock has a market capitalization of $17.98 billion, a PE ratio of 230.76, a price-to-earnings-growth ratio of 2.21 and a beta of 0.34. The stock has a 50 day moving average price of $87.30 and a two-hundred day moving average price of $85.90. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.54 and a current ratio of 5.15.

BioMarin制药公司的股票周五开盘报96.92美元。BioMarin Pharmtics Inc.的股价为70.73美元,为52周低点,52周高点为99.74美元。该股市值为179.8亿美元,市盈率为230.76,市盈率为2.21,贝塔系数为0.34。该股的50日移动均线价格为87.30美元,200日移动均线价格为85.90美元。该公司的负债权益比率为0.24,速动比率为3.54,流动比率为5.15。

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last announced its earnings results on Wednesday, October 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.41). BioMarin Pharmaceutical had a return on equity of 2.50% and a net margin of 4.18%. The firm had revenue of $505.30 million during the quarter, compared to the consensus estimate of $516.03 million. During the same period in the prior year, the company posted ($0.03) EPS. The firm's revenue was up 23.6% on a year-over-year basis. As a group, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 0.88 earnings per share for the current fiscal year.
生物马林制药公司(纳斯达克代码:BMRN-GET Rating)最近一次公布财报是在10月26日星期三。这家生物技术公司公布了本季度每股收益(EPS)(0.04美元),低于普遍预期的0.37美元(0.41美元)。BioMarin制药公司的股本回报率为2.50%,净利润率为4.18%。该公司本季度营收为5.053亿美元,而市场普遍预期为5.1603亿美元。去年同期,该公司公布了每股收益(0.03美元)。该公司的收入同比增长了23.6%。作为一个整体,股票分析师预计BioMarin制药公司本财年的每股收益将为0.88美元。

Analyst Ratings Changes

分析师评级发生变化

Several equities analysts have commented on BMRN shares. JPMorgan Chase & Co. dropped their target price on BioMarin Pharmaceutical from $140.00 to $112.00 and set an "overweight" rating for the company in a research report on Monday, October 24th. Barclays increased their target price on BioMarin Pharmaceutical from $112.00 to $125.00 and gave the company an "overweight" rating in a research report on Thursday, August 4th. SVB Leerink increased their target price on BioMarin Pharmaceutical from $115.00 to $122.00 and gave the company an "outperform" rating in a research report on Thursday, August 4th. Cantor Fitzgerald raised their price objective on BioMarin Pharmaceutical from $110.00 to $115.00 in a research report on Wednesday, October 12th. Finally, Royal Bank of Canada raised their price objective on BioMarin Pharmaceutical from $90.00 to $95.00 and gave the stock a "sector perform" rating in a research report on Thursday, October 13th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average target price of $111.07.

几位股票分析师对BMRN的股票发表了评论。摩根大通将其对BioMarin制药公司的目标价从140.00美元下调至112.00美元,并在24日星期一的一份研究报告中对该公司设定了“增持”评级。巴克莱在周四的一份研究报告中将BioMarin Pharmtics的目标价从112.00美元上调至125.00美元,并给予该公司“增持”评级。8月4日,SVB Leerink在一份研究报告中将他们对BioMarin Pharmtics的目标价从115.00美元上调至122.00美元,并给予该公司“跑赢大盘”的评级。10月12日,周三,坎托·菲茨杰拉德在一份研究报告中将他们对BioMarin制药公司的目标价从110.00美元上调至115.00美元。最后,加拿大皇家银行在10月13日(星期四)的一份研究报告中将他们对BioMarin Pharmtics的目标价从90美元上调至95.00美元,并给出了该股“行业表现”的评级。两名股票研究分析师将该股评级为持有,12名分析师给予该公司买入评级。根据MarketBeat.com的数据,BioMarin制药目前的共识评级为“中等买入”,平均目标价为111.07美元.

Insider Buying and Selling

内幕买卖

In related news, Director Mark J. Alles purchased 3,625 shares of the business's stock in a transaction that occurred on Monday, October 31st. The shares were bought at an average price of $86.75 per share, for a total transaction of $314,468.75. Following the purchase, the director now directly owns 10,905 shares of the company's stock, valued at approximately $946,008.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Mark J. Alles purchased 3,625 shares of the business's stock in a transaction that occurred on Monday, October 31st. The shares were bought at an average price of $86.75 per share, for a total transaction of $314,468.75. Following the purchase, the director now directly owns 10,905 shares of the company's stock, valued at approximately $946,008.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jean Jacques Bienaime sold 1,500 shares of the company's stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $86.55, for a total value of $129,825.00. Following the completion of the sale, the chief executive officer now owns 322,824 shares in the company, valued at approximately $27,940,417.20. The disclosure for this sale can be found here. Insiders have sold 8,500 shares of company stock worth $747,745 in the last 90 days. Insiders own 1.75% of the company's stock.

在相关新闻中,董事马克·J·阿莱斯在10月31日(星期一)的一次交易中购买了3625股该公司的股票。这些股票是以每股86.75美元的平均价格购买的,总交易金额为314,468.75美元。收购完成后,董事现在直接拥有该公司10,905股股票,价值约946,008.75美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过此超链接。在相关新闻中,董事马克·J·阿莱斯在10月31日(星期一)的一次交易中购买了3625股该公司的股票。这些股票是以每股86.75美元的平均价格购买的,总交易金额为314,468.75美元。收购完成后,董事现在直接拥有该公司10,905股股票,价值约946,008.75美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过此超链接。此外,首席执行官Jean Jacques Bienaime在10月31日星期一的一次交易中出售了1,500股公司股票。这只股票的平均售价为86.55美元,总价值为129,825.00美元。出售完成后,首席执行官现在拥有该公司322,824股,价值约27,940,417.20美元。关于这次销售的披露可以找到这里。在过去的90天里,内部人士已经出售了8,500股公司股票,价值747,745美元。内部人士持有该公司1.75%的股份。

BioMarin Pharmaceutical Company Profile

BioMarin制药公司简介

(Get Rating)

(获取评级)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

BioMarin制药公司为患有严重和危及生命的罕见疾病和医疗条件的人开发和销售治疗方法。它的商业产品包括Vimizim,一种治疗粘多糖病IVA型溶酶体储存障碍的酶替代疗法;Naglazyme,一种用于MPS VI患者的N-乙酰半乳糖胺4-硫酸酯酶的重组形式;以及Kuvan,一种专利的6R-BH4的合成口服形式,用于治疗一种遗传性代谢性疾病苯丙酮尿症(PKU)患者。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
  • MarketBeat: Week in Review 11/21 – 11/25
  • Microsoft Shares: Is it Time to Back Up the Truck?
  • Institutional Support for Analog Devices Remains High
  • Three CBD Stocks to Dominate a Budding Industry
  • Is the 60/40 Portfolio Mix Still in Vogue?
  • 免费获取StockNews.com关于BioMarin制药公司(BMRN)的研究报告
  • MarketBeat:回顾一周11/21-11/25
  • 微软股票:是时候备份卡车了吗?
  • 机构对ADI的支持仍然很高
  • 三只CBD股票将主宰一个萌芽行业
  • 60/40的投资组合组合还在《时尚》杂志上流行吗?

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating).

想看看还有哪些对冲基金持有BMRN吗?访问HoldingsChannel.com获取BioMarin制药公司(纳斯达克代码:BMRN-GET Rating)的最新13F备案文件和内幕交易信息。

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

获得《BioMarin药学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioMarin制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发